Genmab — Juni 2018
-
EL> It looks like strong data. Is it somerhing we should be concerned about as Genmab investors?
-
Ok tak Sukker
-
Yes, and data are far from superior. Little better on side effects (neutropenia) and IRR. Median prior therapies 1 more than similar darastudies, but nevetheless dara-pom-dex had 76% pts with >=3 prior therapies and better ORR. Mor202 "mono" (with dex) lower ORR than dara mono. 2 hour infusion shortened to 30 minutes is not bad, but no sc version in sight.
-
The combination of ATRA plus Daratumumab induced Fc-dependent conjugate formation and cytotoxicity among AML blasts in vitro. Combination treatment also led to reduction in tumor volume and resulted in increased overall survival in murine engraftment models of AML
-
Mon ikke forklaringen skal findes her på faldet http://borsen.dk/nyheder/politik/artikel/1/364346/trump_bekraefter_toldkrig_mod_kina_for_50_mia_dollar_-_og_der_kan_komme_mere.html?utm_source=forside&utm_campaign=nyhed_01
-
Det tror jeg ikke er årsagen. Det sædvanlige...nogle tjener på at presse kursen ned..:-(
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Såvidt jeg kan læse viser reagensglas forsøg effekt af Dara ved akut myeloid leukæmi ?